Cancer Immunotherapy Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025

Published on : Dec-2019 | List of Tables : 30 | List of Figures : 115 | No. of Pages : 170 | Report Code : FACT4367MR | Format :

Cancer Immunotherapy Market to Register Double-digit Growth in 2020, as Conventional Therapies Lose Sheen

Conventional cancer treatment involving chemotherapy, radiation therapy, and surgeries, have led to an alarmingly large number of relapse cases of cancer. This, inadvertently, is leading to the development of combination therapies, including immunotherapy as the first line of treatment for cancer. Also, imminent patent expiration of branded drugs is providing new growth avenues for the development of biologics and biosimilar products. This would ensure long-term supply of cancer therapeutics at relatively low prices.

The aforementioned dynamics point towards high growth prospects of the cancer immunotherapy market, which have been further analysed at length in an exclusive study published by Fact.MR. The study indicates that, players in the cancer immunotherapy market space can expect a marginal rise in the demand for cancer immunotherapy, with an estimated CAGR of 15% during the forecast period (2020-2025).

growth opportunities in key segments in cancer immunotherapy market

For detailed insights on market taxonomy, request a sample copy of the report here.

Distribution Partnerships with Hospitals and Clinics

Hospitals remain the most favoured medical settings, as these institutions are equipped with advanced facilities to allow for effective diagnosis and treatment. High adoption of advanced diagnostics and treatment equipment, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by hospitals. These factors are collectively expected to lead to hospitals accounting for around 61% share of the cancer immunotherapy market by 2025.

Relatively short wait times and ease of getting appointments are projected to widen the patient base opting for clinic-based healthcare. Progressive growth in the demand for quality cancer therapeutics in clinics is influencing clinicians to focus on offering cancer immunotherapy to patients, which is driving the exponential adoption of cancer therapeutics in clinics.

High Capital Requisites for R&D Activities Remain Key Dilemma for Market Players

Several studies show that, cancer is an extremely complex disease, and there is no single cure that can prove to be effective for all patients. However, players in the cancer immunotherapy market leverage this opportunity to reach the optimum efficacy level of therapeutics to treat cancer with minimal side-effects. The key requisite to achieve product innovation is high working capital for experimentation and clinical trials, which poses challenges for manufacturers. Besides this, the risk of drug rejection leads to the wastage of resources. According to the study, only 5% of anticancer drugs gain commercial license, post the success of Phase III trials, which is indicative of the high rejection rate of therapeutics in the cancer immunotherapy market.

market share analysis in key regions in cancer immunotherapy market

For detailed regional analysis, request a sample copy of the report here.

Market Performance of Developing Regions to Surpass Growth of Developed Regions

North America, followed by Europe, leads the global cancer immunotherapy market. However, these regions stand to lose market share to Asia Pacific, Latin America, and the Middle East and Africa during the forecast period. Favourable dynamics such as progressive improvements in healthcare infrastructure and government initiatives underpinning the R&D activities of players complement the growth of the cancer immunotherapy markets in these regions. For instance, market players are eligible to receive benefits from the U.S. federal government, such as tax exemptions and market exclusivity, under the Orphan Drug Act.

However, there have been gradual improvements in the quality of healthcare services, increase in accessibility of patients to hospitals and clinics, and growing number of awareness campaigns regarding the diagnosis and treatment of cancer in developing regions. Sensing expansion opportunities in Asia Pacific, Latin America, and the Middle East and Africa, a shift of market focus from developed regions to developing regions is being witnessed among market players. On account of this, developing regions are likely to witness relatively high growth at an average CAGR of 15% over a 14% CAGR for developed regions.

Cancer Immunotherapy Market – Scope of the Study

This report provides forecasts and analysis of the cancer immunotherapy market. This exclusive study also offers analytical data for the historical period (2016-2019) along with forecasts from 2020 to 2025 in terms of revenue (US$ Mn). The report on the global cancer immunotherapy market includes macroeconomic as well as microeconomic growth indicators. The study provides information on the key drivers and restraints influencing the growth of the cancer immunotherapy market, and their impact on each region during the forecast period. The report also comprises a study of the current challenges impeding the adoption rate and opportunities for manufacturers in the cancer immunotherapy market. This comprehensive study also includes value chain analysis, with a list of vendors and industry stakeholders at each node in the value chain, pipeline snapshot, and cancer epidemiology in every region.

In order to provide stakeholders with a comprehensive view of the cancer immunotherapy market, authors of the report have included detailed competitive analysis and key players with unique selling propositions. The dashboard provides a detailed comparison of manufacturers operating in the cancer immunotherapy market, on parameters such as collective market share and geographic concentration. This detailed study on the cancer immunotherapy market offers incisive insights regarding significant dynamics influencing the movement of the cancer immunotherapy landscape during the forecast period.

Authors of the cancer immunotherapy market report have taken ample care to track the latest market movements to ensure that only accurate information reaches to stakeholders. The study helps these stakeholders in gaining an edge over their competitors. This exclusive guide also tracks the current as well as future trends that are likely to influence the growth of the cancer immunotherapy market during the forecast period. To add to that, the analysis also discusses the threat of substitutes and new entrants, which provides a brief idea regarding the future growth course of the cancer immunotherapy market.

Cancer Immunotherapy Market – Assessment of Key Segments

The study encompasses market attractiveness analysis, by therapy, cancer type, end user, and region. Market size and forecasts for each segment have been provided in the context of global and regional markets. The cancer immunotherapy market has been analysed based on expected demand. All key end users have been considered, and potential applications have been estimated on the basis of secondary sources and feedback from primary respondents. Regional demand patterns have been considered while estimating the market for various end users of cancer immunotherapy in different regions.

Therapy

Cancer Type

End User

Region

Monoclonal Antibodies

Lung Cancer

Hospitals

North America

Immune Checkpoint Inhibitors

  • PD-1/PD-L1
  • CTLA-4

Colorectal Cancer

Ambulatory Surgical Centres

Europe

Immune System Modulators

Breast Cancer

Cancer Research Centres

Asia Pacific

Cancer Vaccines

Prostate Cancer

Clinics

Latin America

Others

Melanoma

 

Middle East & Africa

 

Blood Cancer

 

 

 

Others

 

 

The report provides a detailed competitive dashboard and company profiles of key participants operating in the global market. Some of the key players in the global cancer immunotherapy market include Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline Plc., F.Hoffmann-La Roche Ltd., Janssen Biotech, Inc., Novartis AG, Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals.

Cancer Immunotherapy Market – Research Methodology

A number of primary and secondary sources were consulted during the course of the study on the cancer immunotherapy market. Secondary sources include NCBI, cancerresearch.org, WHO, FDA, Google Books, articles, company annual reports, websites, press releases, and publications.

The top-down approach has been used to estimate the cancer immunotherapy market by region. Market numbers for global therapy and therapeutic area segments have been derived using the bottom-up approach, which is cumulative of each region’s demand. Company-level market share has been derived on the basis of revenues reported by key players in the cancer immunotherapy market space. The cancer immunotherapy market has been forecast based on current currency rates.

Request research methodology of this report.

1.  Preface

   1.1. Market Definition and Scope

   1.2. Market Segmentation

   1.3. Key Research Objectives

   1.4. Research Highlights

2.  Assumptions and Research Methodology

3.  Executive Summary : Global Cancer Immunotherapy Market

4.  Market Overview

   4.1. Introduction

       4.1.1. Market Definition

       4.1.2. Industry Evolution / Developments

   4.2. Overview

   4.3. Key Market Indicators

       4.3.1. Region/Country Specific

       4.3.2. Product/Therapeutic Area Specific

       4.3.3. Target Market Specific – Global Scenario

   4.4. Market Dynamics

       4.4.1. Drivers

       4.4.2. Restraints

       4.4.3. Opportunity

       4.4.4. Trends

   4.5. Global Cancer Immunotherapy Market Analysis and Forecasts, 2020–2025

       4.5.1. Market Revenue Projections (US$ Mn)

   4.6. Cancer Immunotherapy Market - Global Supply Demand Scenario

   4.7. Porter’s Five Force Analysis

   4.8. Value Chain Analysis

       4.8.1. List of active market participants

           4.8.1.1. Manufacturers

           4.8.1.2. Distributors

       4.8.2. Forward – Backward Integration Scenario

   4.9. Market Outlook

   4.10. Pipeline Snapshot

   4.11. Cancer Epidemiology

   4.12. Reimbursement Scenario and Patient Support Programs Overview

5. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapy Type

   5.1. Introduction & Definition

   5.2. Key Findings / Developments

   5.3. Market Value Forecast By Therapy Type, 2020–2025

       5.3.1. Monoclonal Antibodies

       5.3.2. Immune Checkpoint Inhibitors

           5.3.2.1. PD-1/PD-L1

           5.3.2.2. CTLA-4

       5.3.3. Immune System Modulators

       5.3.4. Cancer Vaccines

       5.3.5. Others

   5.4. Market Attractiveness By Therapy 

6. Global Cancer Immunotherapy Market Analysis and Forecasts, By End User 

   6.1. Introduction & Definition

   6.2. Key Findings / Developments

   6.3. Market Value  Forecast By End User, 2020–2025

       6.3.1. Hospitals

       6.3.2. ASC's

       6.3.3. Cancer Research Institutes

       6.3.4. Clinics

   6.4. Market Attractiveness By End User 

7. Global Cancer Immunotherapy Market Analysis and Forecasts, By Therapeutic Area 

   7.1. Introduction & Definition

   7.2. Key Findings / Developments

   7.3. Market Value  Forecast By Therapeutic Area, 2020–2025

       7.3.1. Lung Cancer

       7.3.2. Colorectal Cancer

       7.3.3. Breast Cancer

       7.3.4. Prostate Cancer

       7.3.5. Melanoma

       7.3.6. Blood Cancers

       7.3.7. Others

   7.4. Market Attractiveness By Therapeutic Area 

8. Global Cancer Immunotherapy Market Analysis and Forecasts, By Region

   8.1. Key Findings

   8.2. Policies and Regulations

   8.3. Market Value  Forecast By Region

       8.3.1. North America 

       8.3.2. Europe 

       8.3.3. Asia Pacific 

       8.3.4. Latin America 

       8.3.5. Middle East and Africa 

   8.4. Market Attractiveness By Region

9. North America Cancer Immunotherapy Market Analysis and Forecast

   9.1. Introduction

       9.1.1. Key Findings

       9.1.2. Policies and Regulations

   9.2. Market Value Forecast By Therapy Type, 2020–2025

       9.2.1. Monoclonal Antibodies

       9.2.2. Immune Checkpoint Inhibitors

           9.2.2.1. PD-1/PD-L1

           9.2.2.2. CTLA-4

       9.2.3. Immune System Modulators

       9.2.4. Cancer Vaccines

       9.2.5. Others

   9.3. Market Value  Forecast By End User, 2020–2025

       9.3.1. Hospitals

       9.3.2. ASC's

       9.3.3. Cancer Research Institutes

       9.3.4. Clinics

   9.4. Market Value  Forecast By Therapeutic Area, 2020–2025

       9.4.1. Lung Cancer

       9.4.2. Colorectal Cancer

       9.4.3. Breast Cancer

       9.4.4. Prostate Cancer

       9.4.5. Melanoma

       9.4.6. Blood Cancer

       9.4.7. Others

   9.5. Market Value  Forecast By Country, 2020–2025

       9.5.1. U.S.

       9.5.2. Canada

   9.6. Market Attractiveness Analysis 

       9.6.1. By Therapy Type

       9.6.2. By End User 

       9.6.3. By Therapeutic Area 

       9.6.4. By Country

10. Europe Cancer Immunotherapy Market Analysis and Forecast

   10.1. Introduction

       10.1.1. Key Findings

       10.1.2. Policies and Regulations

   10.2. Market Value  Forecast By Therapy Type, 2020–2025

       10.2.1. Monoclonal Antibodies

       10.2.2. Immune Checkpoint Inhibitors

           10.2.2.1. PD-1/PD-L1

           10.2.2.2. CTLA-4

       10.2.3. Immune System Modulators

       10.2.4. Cancer Vaccines

       10.2.5. Others

   10.3. Market Value Forecast By End User, 2020–2025

       10.3.1. Hospitals

       10.3.2. ASC's

       10.3.3. Cancer Research Institutes

       10.3.4. Clinics

   10.4. Market Value Forecast By Therapeutic Area, 2020–2025

       10.4.1. Lung Cancer

       10.4.2. Colorectal Cancer

       10.4.3. Breast Cancer

       10.4.4. Prostate Cancer

       10.4.5. Melanoma

       10.4.6. Blood Cancer

       10.4.7. Others

   10.5. Market Value Forecast By Country, 2020–2025

       10.5.1. Germany

       10.5.2. U.K. 

       10.5.3. France

       10.5.4. Spain

       10.5.5. Italy

       10.5.6. Rest of Europe

   10.6. Market Attractiveness Analysis 

       10.6.1. By Therapy Type

       10.6.2. By End User 

       10.6.3. By Therapeutic Area 

       10.6.4. By Country

11. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast

   11.1. Introduction

       11.1.1. Key Findings

       11.1.2. Policies and Regulations

   11.2. Market Value Forecast By Therapy Type, 2020–2025

       11.2.1. Monoclonal Antibodies

       11.2.2. Immune Checkpoint Inhibitors

           11.2.2.1. PD-1/PD-L1

           11.2.2.2. CTLA-4

       11.2.3. Immune System Modulators

       11.2.4. Cancer Vaccines

       11.2.5. Others

   11.3. Market Value Forecast By End User, 2020–2025

       11.3.1. Hospitals

       11.3.2. ASC's

       11.3.3. Cancer Research Institutes

       11.3.4. Clinics

   11.4. Market Value Forecast By Therapeutic Area, 2020–2025

       11.4.1. Lung Cancer

       11.4.2. Colorectal Cancer

       11.4.3. Breast Cancer

       11.4.4. Prostate Cancer

       11.4.5. Melanoma

       11.4.6. Blood Cancer

       11.4.7. Others

   11.5. Market Value Forecast By Country, 2020–2025

       11.5.1. Japan

       11.5.2. China

       11.5.3. India

       11.5.4. Australia

       11.5.5. New Zealand

       11.5.6. Rest of APAC

   11.6. Market Attractiveness Analysis 

       11.6.1. By Therapy Type

       11.6.2. By End User 

       11.6.3. By Therapeutic Area 

       11.6.4. By Country

12. Latin America Cancer Immunotherapy Market Analysis and Forecast

   12.1. Introduction

       12.1.1. Key Findings

       12.1.2. Policies and Regulations

   12.2. Market Value Forecast By Therapy Type, 2020–2025

       12.2.1. Monoclonal Antibodies

       12.2.2. Immune Checkpoint Inhibitors

           12.2.2.1. PD-1/PD-L1

           12.2.2.2. CTLA-4

       12.2.3. Immune System Modulators

       12.2.4. Cancer Vaccines

       12.2.5. Others

   12.3. Market Value Forecast By End User, 2020–2025

       12.3.1. Hospitals

       12.3.2. ASC's

       12.3.3. Cancer Research Institutes

       12.3.4. Clinics

   12.4. Market Value Forecast By Therapeutic Area, 2020–2025

       12.4.1. Lung Cancer

       12.4.2. Colorectal Cancer

       12.4.3. Breast Cancer

       12.4.4. Prostate Cancer

       12.4.5. Melanoma

       12.4.6. Blood Cancer

       12.4.7. Others

   12.5. Market Value Forecast By Country, 2020–2025

       12.5.1. Brazil

       12.5.2. Mexico

       12.5.3. Rest of Latin America

   12.6. Market Attractiveness Analysis 

       12.6.1. By Therapy Type

       12.6.2. By End User 

       12.6.3. By Therapeutic Area 

       12.6.4. By Country

13. Middle East and Africa Cancer Immunotherapy Market Analysis and Forecast

   13.1. Introduction

       13.1.1. Key Findings

       13.1.2. Policies and Regulations

   13.2. Market Value  Forecast By Therapy Type, 2020–2025

       13.2.1. Monoclonal Antibodies

       13.2.2. Immune Checkpoint Inhibitors

           13.2.2.1. PD-1/PD-L1

           13.2.2.2. CTLA-4

       13.2.3. Immune System Modulators

       13.2.4. Cancer Vaccines

       13.2.5. Others

   13.3. Market Value  Forecast By End User, 2020–2025

       13.3.1. Hospitals

       13.3.2. ASC's

       13.3.3. Cancer Research Institutes

       13.3.4. Clinics

   13.4. Market Value  Forecast By Therapeutic Area, 2020–2025

       13.4.1. Lung Cancer

       13.4.2. Colorectal Cancer

       13.4.3. Breast Cancer

       13.4.4. Prostate Cancer

       13.4.5. Melanoma

       13.4.6. Blood Cancer

       13.4.7. Others

   13.5. Market Value Forecast By Country, 2020–2025

       13.5.1. Saudi Arabia

       13.5.2. UAE

       13.5.3. South Africa

       13.5.4. Rest of MEA

   13.6. Market Attractiveness Analysis 

       13.6.1. By Therapy Type

       13.6.2. By End User 

       13.6.3. By Therapeutic Area 

       13.6.4. By Country

14. Competition Landscape

   14.1. Market Player – Competition Matrix (By Tier and Size of companies)

   14.2. Market Share Analysis By Company (2015)

   14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

       14.3.1. Amgen, Inc.

           14.3.1.1. Overview

           14.3.1.2. Financials

           14.3.1.3. Recent Developments

           14.3.1.4. Strategy 

       14.3.2. AstraZenca Plc

           14.3.2.1. Overview

           14.3.2.2. Financials

           14.3.2.3. Recent Developments

           14.3.2.4. Strategy

       14.3.3. Bristol-Myers Squibb Company

           14.3.3.1. Overview

           14.3.3.2. Financials

           14.3.3.3. Recent Developments

           14.3.3.4. Strategy

       14.3.4. Eli Lilly and Company

           14.3.4.1. Overview

           14.3.4.2. Financials

           14.3.4.3. Recent Developments

           14.3.4.4. Strategy

       14.3.5. F.Hoffmann-La Roche Ltd.

           14.3.5.1. Overview

           14.3.5.2. Financials

           14.3.5.3. Recent Developments

           14.3.5.4. Strategy

       14.3.6. GlaxoSmithKline Plc.

           14.3.6.1. Overview

           14.3.6.2. Financials

           14.3.6.3. Recent Developments

           14.3.6.4. Strategy

       14.3.7. Janssen Biotech, Inc.

           14.3.7.1. Overview

           14.3.7.2. Financials

           14.3.7.3. Recent Developments

           14.3.7.4. Strategy

       14.3.8. Merck & Co.

           14.3.8.1. Overview

           14.3.8.2. Financials

           14.3.8.3. Recent Developments

           14.3.8.4. Strategy

       14.3.9. Novartis AG

           14.3.9.1. Overview

           14.3.9.2. Financials

           14.3.9.3. Recent Developments

           14.3.9.4. Strategy

       14.3.10. Pfizer, Inc.

           14.3.10.1. Overview

           14.3.10.2. Financials

           14.3.10.3. Recent Developments

           14.3.10.4. Strategy

       14.3.11. Sanofi

           14.3.11.1. Overview

           14.3.11.2. Financials

           14.3.11.3. Recent Developments

           14.3.11.4. Strategy

       14.3.12. Spectrum Pharmaceuticals, Inc.

           14.3.12.1. Overview

           14.3.12.2. Financials

           14.3.12.3. Recent Developments

           14.3.12.4. Strategy

       14.3.13. Takeda Pharmaceuticals

           14.3.13.1. Overview

           14.3.13.2. Financials

           14.3.13.3. Recent Developments

           14.3.13.4. Strategy

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Cancer Immunotherapy Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2025